In terms of safety, risks of neuropathy, hospitalizations, and anemia were significantly higher with RVD compared with RD or VD.
Belantamab mafodotin plus bortezomib and dexamethasone improved OS vs daratumumab plus bortezomib and dexamethasone in patients with relapsed/refractory MM.
Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.
Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.
This article highlights the top gynecologic cancer research published on Cancer Therapy Advisor in 2024.
Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.
A lack of mask mandates at cancer centers and elsewhere has left cancer patients feeling unsafe and abandoned by society.
Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.
Fedratinib reduced symptoms and spleen volume in patients with MDS or MPNs in a phase 2 trial.
Daratumumab and lenalidomide improved survival outcomes over lenalidomide and dexamethasone in frail patients with newly diagnosed MM.
Teclistamab maintenance, given alone or in combination with lenalidomide, demonstrated “unprecedented efficacy” in multiple myeloma patients.
